Physician profile
Shailesh Patel
NPI 1144274861
$9,910.15
in general payments reported to CMS, 2019-2025
29 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,770 · 2020: $84.46 · 2021: $279 · 2022: $365 · 2023: $545 · 2024: $646 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,394 · Education: $17.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,394.35 |
| Education | $17.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $6,424.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $492.82 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $390.06 | 2019-2025 | Krystexxa, Tavneos, Aranesp |
| Astrazeneca Pharmaceuticals LP | $389.47 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $221.67 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $209.09 | 2022-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $175.13 | 2019-2024 | Rayaldee |
| Akebia Therapeutics INC | $156.41 | 2020-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $144.22 | 2024-2025 | Ibsrela |
| Vantive US Healthcare LLC | $128.34 | 2025 | |
| Novartis Pharmaceuticals Corporation | $123.91 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $103.31 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $102.32 | 2021-2022 | |
| Daiichi Sankyo INC. | $94.33 | 2023-2024 | Injectafer |
| Chiesi USA, INC. | $92.83 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $86.90 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.20 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $81.42 | 2021-2025 | Benlysta, Shingrix, Arexvy |
| Lilly USA, LLC | $76.98 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $68.22 | 2019-2023 | Veltassa, Korsuva |
| Alexion Pharmaceuticals, INC. | $61.93 | 2022-2024 | Ultomiris, Soliris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.50 | 2023-2024 | Jynarque |
| Takeda Pharmaceuticals U.S.A., INC. | $37.39 | 2022-2023 | Livtencity |
| Fresenius USA Marketing, INC. | $23.99 | 2023 | Velphoro |
| Novo Nordisk INC | $23.36 | 2025 | Ozempic, Rybelsus |
| Cormedix INC. | $20.94 | 2025 | Defencath |
| Genzyme Corporation | $18.13 | 2019 | |
| Apellis Pharmaceuticals, INC. | $17.42 | 2025 | |
| Ani Pharmaceuticals, INC. | $16.86 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shailesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.